细胞衰老与特发性肺纤维化药物治疗研究进展  

Research progress in cellular senescence and drug therapy of idiopathic pulmonary fibrosis

作　　者：任正肖 张颖颖 车萍 李紫薇 朱庆均 REN Zheng-xiao;ZHANG Ying-ying;CHE Ping;LI Zi-wei;ZHU Qing-jun(Experimental Center,Dept of Microbiology,Innovative Institute of Chinese Medicine and Pharmacy,Shandong University of Traditional Chinese Medicine,Jinan 250355,China)

机构地区：[1]山东中医药大学实验中心,山东中医药大学中医学院微生物教研室,山东中医药大学中医药创新研究院,山东济南250355

出　　处：《中国药理学通报》2024年第4期601-605,共5页Chinese Pharmacological Bulletin

基　　金：山东省自然科学基金项目(No ZR2020MH384);山东省重点研发计划(重大科技创新工程)(No 2020CXGC010505)。

摘　　要：特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种病因不明的破坏性肺部疾病,它的特点是细胞外基质蛋白(如胶原蛋白和纤连蛋白)在肺间质中沉积,导致呼吸衰竭。我们对IPF的病理生物学的理解仍然不完整;然而,人们普遍认为,衰老是该疾病的主要危险因素。衰老是一个复杂的过程,以不可逆的细胞周期停滞和分泌衰老相关的表型(senescence-associated secretory phenotype,SASP)为特征,导致衰老细胞不断累积和炎症发生。细胞衰老与IPF疾病进展密切相关。该文主要探讨细胞衰老的分子机制,端粒缩短、线粒体功能障碍、自噬不足及细胞凋亡抵抗等细胞衰老相关的各种诱发因素在IPF发病中的作用以及用于治疗IPF疾病的抗衰老药物,为将来治疗IPF提供理论依据和治疗方法。Idiopathic pulmonary fibrosis(IPF)is a devastating lung disease of unknown etiology characterized by the deposition of extracellular matrix proteins,such as collagen and fibronectin,in the interstitium of the lung,leading to respiratory failure.Our understanding of the pathobiology of IPF remains incomplete;however,it is generally accepted that aging is a major risk factor for the disease.Senescence is a complex process characterized by irreversible cell cycle arrest and secretory senescence-associated phenotype(SASP),leading to the continuous accumulation of senescent cells and the development of inflammation.Cellular senescence is closely related to pulmonary fibrosis disease progression.This review mainly discusses the molecular mechanism of cellular senescence,telomere shortening,mitochondrial dysfunction,autophagy deficiency,apoptosis resistance related to cellular cellular in the pathogenesis of IPF and the anti-aging drugs used to treat IPF,so as to provide the theoretical basis and therapeutic methods for the future treatment of IPF.

关 键 词：特发性肺纤维化 细胞衰老 衰老相关表型 端粒缩短 线粒体功能障碍 自噬不足 细胞凋亡抵抗 治疗 

分 类 号：R-05[医药卫生] R329.24R339.38R563R563.130.5